StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

TG Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $225.80M, up 84.8% year over year. For fiscal 2025 it was $160.22M, up 69.9% from the year before. Over ten years it grew 12.9% a year on average. The highest annual figure on record is $222.58M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$160.22M+69.9%
FY2024Dec 31, 2024$94.29M+23.8%
FY2023Dec 31, 2023$76.19M-39.2%
FY2022Dec 31, 2022$125.35M-43.7%
FY2021Dec 31, 2021$222.58M+34.2%
FY2020Dec 31, 2020$165.90M+7.6%
FY2019Dec 31, 2019$154.18M-3.3%
FY2018Dec 31, 2018$159.39M+55.5%
FY2017Dec 31, 2017$102.53M+48.1%
FY2016Dec 31, 2016$69.23M+45.1%
FY2015Dec 31, 2015$47.71M+19.0%
FY2014Dec 31, 2014$40.09M+193.4%
FY2013Dec 31, 2013$13.66M-35.0%
FY2012Dec 31, 2012$21.03M+6325.0%
FY2011Dec 31, 2011$327.28K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$95.34M+200.0%
Q1 FY2026Mar 31, 2026$48.40M+4.4%
Q4 FY2025Dec 31, 2025$41.19M+72.5%
Q3 FY2025Sep 30, 2025$40.88M+103.0%
Q2 FY2025Jun 30, 2025$31.78M+81.0%
Q1 FY2025Mar 31, 2025$46.36M+41.7%
Q4 FY2024Dec 31, 2024$23.87M+36.8%
Q3 FY2024Sep 30, 2024$20.14M+36.5%
Q2 FY2024Jun 30, 2024$17.56M-37.6%
Q1 FY2024Mar 31, 2024$32.72M+106.2%
Q4 FY2023Dec 31, 2023$17.45M-41.1%
Q3 FY2023Sep 30, 2023$14.75M-29.1%
Q2 FY2023Jun 30, 2023$28.12M+4.6%
Q1 FY2023Mar 31, 2023$15.87M-67.0%
Q4 FY2022Dec 31, 2022$29.64M-52.7%
Q3 FY2022Sep 30, 2022$20.80M-60.0%
Q2 FY2022Jun 30, 2022$26.87M-40.1%
Q1 FY2022Mar 31, 2022$48.04M-23.9%
Q4 FY2021Dec 31, 2021$62.65M+45.8%
Q3 FY2021Sep 30, 2021$51.97M+3.0%
Q2 FY2021Jun 30, 2021$44.87M+23.1%
Q1 FY2021Mar 31, 2021$63.09M+75.2%
Q4 FY2020Dec 31, 2020$42.96M+38.8%
Q3 FY2020Sep 30, 2020$50.46M-13.0%
Q2 FY2020Jun 30, 2020$36.45M+10.9%
Q1 FY2020Mar 31, 2020$36.02M+11.2%
Q4 FY2019Dec 31, 2019$30.94M-40.8%
Q3 FY2019Sep 30, 2019$57.99M+73.6%
Q2 FY2019Jun 30, 2019$32.87M-15.1%
Q1 FY2019Mar 31, 2019$32.39M-7.5%
Q4 FY2018Dec 31, 2018$52.28M+101.1%
Q3 FY2018Sep 30, 2018$33.40M+23.0%
Q2 FY2018Jun 30, 2018$38.70M+44.9%
Q1 FY2018Mar 31, 2018$35.02M+54.4%
Q4 FY2017Dec 31, 2017$26.00M+16.7%
Q3 FY2017Sep 30, 2017$27.15M+24.5%
Q2 FY2017Jun 30, 2017$26.71M–
Q1 FY2017Mar 31, 2017$22.68M–
Q4 FY2016Dec 31, 2016$22.28M–
Q3 FY2016Sep 30, 2016$21.80M–

More TG Therapeutics figures

See a number that looks wrong?